Theravance Biopharma (NASDAQ:TBPH) Shares Pass Above Fifty Day Moving Average – Should You Sell?

Theravance Biopharma, Inc. (NASDAQ:TBPH) crossed above its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of $16.62 and traded as high as $17.00. Theravance Biopharma shares last traded at $16.97, with a volume of 317,513 shares.

Wall Street Analysts Forecast Growth

TBPH has been the subject of a number of research analyst reports. TD Cowen increased their target price on shares of Theravance Biopharma from $13.00 to $15.00 and gave the company a “hold” rating in a report on Monday, March 23rd. B. Riley Financial lifted their price objective on Theravance Biopharma from $14.00 to $17.00 and gave the stock a “neutral” rating in a research report on Tuesday, April 7th. BTIG Research downgraded Theravance Biopharma from a “buy” rating to a “neutral” rating in a research report on Monday, June 29th. Zacks Research downgraded shares of Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a research report on Monday, June 8th. Finally, HC Wainwright lowered Theravance Biopharma from a “buy” rating to a “neutral” rating and raised their price objective for the company from $15.00 to $17.00 in a research report on Tuesday, July 7th. Eight investment analysts have rated the stock with a Hold rating, According to data from MarketBeat.com, Theravance Biopharma presently has an average rating of “Hold” and an average price target of $19.40.

Theravance Biopharma Trading Down 0.2%

The business’s 50-day simple moving average is $16.62 and its two-hundred day simple moving average is $17.17. The company has a market capitalization of $872.79 million, a PE ratio of 7.70 and a beta of 0.17.

Theravance Biopharma (NASDAQ:TBPH) last released its quarterly earnings results on Tuesday, March 31st. The biopharmaceutical company reported ($0.10) EPS for the quarter. Theravance Biopharma had a return on equity of 18.84% and a net margin of 104.34%.The business had revenue of $17.70 million during the quarter. On average, analysts forecast that Theravance Biopharma, Inc. will post 1.54 EPS for the current year.

Insider Buying and Selling

In other news, major shareholder Eli Samaha sold 273,871 shares of the stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $17.23, for a total transaction of $4,718,797.33. Following the completion of the transaction, the insider directly owned 9,237,279 shares in the company, valued at approximately $159,158,317.17. This represents a 2.88% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, SVP Rhonda Farnum sold 13,314 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $16.39, for a total transaction of $218,216.46. Following the sale, the senior vice president directly owned 232,457 shares of the company’s stock, valued at $3,809,970.23. The trade was a 5.42% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 350,011 shares of company stock worth $6,008,309. 7.65% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in TBPH. Wedge Capital Management L L P NC acquired a new stake in shares of Theravance Biopharma in the 2nd quarter valued at about $2,190,000. Empowered Funds LLC bought a new stake in Theravance Biopharma in the first quarter valued at about $900,000. Bank of America Corp DE increased its holdings in Theravance Biopharma by 78.2% in the first quarter. Bank of America Corp DE now owns 189,155 shares of the biopharmaceutical company’s stock valued at $3,070,000 after buying an additional 82,978 shares during the last quarter. California State Teachers Retirement System raised its stake in Theravance Biopharma by 1,649.4% during the first quarter. California State Teachers Retirement System now owns 40,761 shares of the biopharmaceutical company’s stock valued at $662,000 after buying an additional 38,431 shares in the last quarter. Finally, Quantinno Capital Management LP lifted its holdings in Theravance Biopharma by 32.9% during the 1st quarter. Quantinno Capital Management LP now owns 18,038 shares of the biopharmaceutical company’s stock worth $293,000 after buying an additional 4,463 shares during the last quarter. 99.10% of the stock is owned by institutional investors and hedge funds.

Theravance Biopharma Company Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.